

Palboxen 125mg Capsule (Palbociclib)
Manufactured By
Everest
Pack Of
21
Salt Composition
Palbociclib
Storage
Store below 30°C
ALL SUBSTITUTES
Overview
The Palboxen 125mg Capsule contains palbociclib, an oral targeted anticancer medicine that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes help cells progress through the cell cycle. Blocking them can slow the growth of hormone-receptor-positive breast cancer cells. The Palbociclib 125mg capsule is used with endocrine therapy for selected patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
The endocrine partner may be an aromatase inhibitor or fulvestrant depending on menopausal status, previous treatment, and clinical setting. Palboxen 125mg Capsule is a prescription medicine and requires regular blood-count monitoring because neutropenia is common. The exact formulation matters: capsules and tablets can have different food instructions, so patients should follow the specific pack insert and oncologist’s directions.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | Palboxen |
| Active ingredient | Palbociclib |
| Strength / presentation | 125 mg |
| Form | Capsule |
| Medicine class | CDK4/6 inhibitor |
| Manufacturer / marketer | Everest |
| Pack | 21 capsules |
| Prescription | Yes |
Uses and Indications
Head and neck cancer, kidney canPalbociclib capsules are used in combination with endocrine therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. It may be combined with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant in patients whose disease has progressed after endocrine therapy, depending on the approved label and patient profile.
Pre-menopausal or perimenopausal patients generally require ovarian suppression when appropriate. Palbociclib 125mg capsules are not used as a stand-alone replacement for endocrine therapy in these settings. Treatment selection considers hormone-receptor and HER2 status, menopausal status, previous therapy, disease burden, organ function, and potential drug interactions.
How Palboxen 125mg Capsule Works
Palbociclib capsule selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases phosphorylate the retinoblastoma protein and help cells move from the G1 phase into the S phase of the cell cycle. In HR-positive, HER2-negative breast cancer, blocking CDK4/6 can slow cell-cycle progression and enhance the effect of endocrine therapy. Bone-marrow precursor cells are also sensitive to this pathway, which is why neutropenia is a frequent treatment-limiting toxicity.
Clinical Evidence for Palboxen 125mg Capsule
Evidence context: The studies below are pivotal or widely cited evidence supporting the Palbociclib 125mg capsule in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.
Side Effects of Palboxen 125mg Capsule
Palboxen 125mg Capsule may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.
Common side effects
- Neutropenia
- Leukopenia
- Fatigue
- Infections
- Nausea
- Stomatitis / mouth sores
- Hair thinning
- Diarrhea
Serious side effects
- Febrile neutropenia / serious infection
- Severe bone-marrow suppression
- Interstitial lung disease / pneumonitis
Critical Safety Warning
Neutropenia is the principal dose-limiting toxicity and can lead to serious infection. Interstitial lung disease/pneumonitis has also been reported. Severe cytopenias require treatment interruption, dose reduction, or discontinuation according to the label.
Palboxen 125mg Capsule Dosage and How To Take It
The standard starting dose is 125 mg orally once daily for 21 consecutive days, followed by 7 days off treatment, creating a 28-day cycle, in combination with appropriate endocrine therapy. Dose reductions for toxicity are commonly 100 mg once daily and then 75 mg once daily. The Palbociclib 125mg capsule is taken with food; tablet formulations have different food instructions, so the formulation on the pack matters. Premenopausal/perimenopausal women receiving an aromatase inhibitor or fulvestrant generally also receive an LHRH agonist.
Administration guidance: Take the Palboxen 125mg Capsule exactly according to the prescribed 28-day cycle, commonly once daily for 21 consecutive days followed by 7 days without the palbociclib 125mg capsule. Because this product is a capsule, follow the capsule-specific instructions; palbociclib 125mg capsules are generally taken with food. Swallow capsules whole and do not open, crush, or chew them. Take the dose at approximately the same time each day. Blood counts are checked before and during treatment, particularly early cycles. The oncologist may delay palbociclib 125mg capsule treatment, interrupt it or reduce the dose for neutropenia or other toxicity. Avoid grapefruit products and discuss all new medicines before starting them.
Palboxen 125mg Capsule Missed Dose
If a dose is missed or vomiting occurs after a dose, do not take an additional dose that day. Take the next dose at the regularly scheduled time.
Safety Advice for Palboxen 125mg Capsule
| Category | Status | Guidance |
|---|---|---|
| Pregnancy | Avoid | Can cause fetal harm. Use effective contraception for the label-specified period after treatment. |
| Male reproductive precautions | Required | Male patients with partners of reproductive potential should follow label-based contraception guidance. |
| Breastfeeding | Avoid | Do not breastfeed during treatment and for the label-specified period after the final dose. |
| CBC | Essential | Check before treatment, early in therapy, and as clinically indicated because neutropenia is common. |
| Lungs | Urgent monitoring | A new or worsening cough, dyspnea, or fever may indicate ILD/pneumonitis. |
| Liver/kidney | Specialist review | Severe organ impairment can affect dosing decisions; follow the current label. |
Monitoring During Palboxen 125mg Capsule Treatment
CBC should be checked before treatment, at the start of each cycle, and around day 15 of the first two cycles, with additional monitoring as clinically indicated. Monitor for fever/infection and respiratory symptoms. Review hepatic impairment and CYP3A interactions.
Practical monitoring checklist
- Complete blood count (CBC) at the label/protocol-recommended intervals
Palboxen 125mg Capsule Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Generic | Palbociclib |
| Brand | Palboxen |
| Manufacturer / marketer | Everest |
| Strength / presentation | 125 mg |
| Form | Capsule |
| Drug class | CDK4/6 inhibitor |
| Mechanism / target | Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). |
| Main indication context | The Palbociclib 125mg capsule is used in combination with endocrine therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. It may be combined with an aromatase inhibitor as initial endocrine-based therapy. |
| Biomarker / selection | HR-positive, HER2-negative breast cancer |
| Administration | Oral |
| Major warning | Severe neutropenia/infection and interstitial lung disease |
| Pack | 21 capsules |
| Storage | Store below 30°C. |
| Prescription required | Yes |
| Key evidence | PALOMA-2, PALOMA-3 |
Palboxen 125mg Capsule Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Strong CYP3A inhibitors | Increase palbociclib capsule exposure | Avoid when possible; if unavoidable, use label-based dose reduction. |
| Strong CYP3A inducers | Can reduce palbociclib exposure | Avoid because efficacy may be reduced. |
| Grapefruit | May increase palbociclib 125mg exposure | Avoid. |
| Sensitive CYP3A substrates | Palbociclib capsules may increase their exposure | Review narrow-therapeutic-index medicines and monitor appropriately. |
FAQs About Palboxen 125mg Capsule
What is the Palboxen 125mg Capsule used for?
The Palboxen 125mg Capsule contains Palbociclib. Its approved uses depend on the cancer type, disease stage, biomarkers where relevant, previous treatment, and the current product label. The oncologist determines whether this medicine fits the treatment plan.
Is Palboxen 125mg Capsule chemotherapy?
This is not traditional cytotoxic chemotherapy; it is a targeted anticancer medicine.
Can the dose be decided from the tablet/capsule/vial strength?
No. The strength printed on the pack is not necessarily the patient dose. Dosing may depend on indication, body size, kidney/liver function, treatment cycle, combination regimen, and toxicity.
What should I do if I develop a fever during Palbociclib 125mg treatment?
Contact the oncology team urgently, especially with medicines that lower white blood cells. Fever during neutropenia can indicate a serious infection requiring rapid assessment.
Can I stop the Palboxen 125mg treatment if side effects occur?
Do not stop or reduce treatment on your own. Many oncology medicines have structured interruption and dose-reduction rules that allow toxicity to be managed safely.
Can I take supplements or herbal medicines with the Princyv 125mg treatment?
Only after discussing them with the oncology team. Herbal products and OTC medicines can alter drug levels, bleeding risk, liver function, or treatment toxicity.
Why is the capsule taken for 21 days and then stopped for 7 days?
The common 21-days-on/7-days-off schedule provides planned recovery time, particularly for blood counts. The exact schedule should match the oncologist's prescription.
Where can I confirm Palbociclib 125mg availability?
Current stock and prescription fulfillment can be confirmed by visiting our website. Availability may vary by location, so it is advised to first check the stock before placing an order.
References
- FDA Ibrance (palbociclib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207103s024lbl.pdf
- EMA Ibrance Product Information / SmPC. https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. https://www.nccn.org/guidelines/guidelines-detail?id=1419
- National library of medicine. Palbociclib. https://pmc.ncbi.nlm.nih.gov/articles/PMC4128689/
Marketer Details
Everest
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.










